ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

KNSA Kiniksa Pharmaceuticals Ltd

19.17
-0.10 (-0.52%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Kiniksa Pharmaceuticals Ltd NASDAQ:KNSA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -0.52% 19.17 15.39 19.65 19.43 19.01 19.23 279,094 01:00:00

Initial Statement of Beneficial Ownership (3)

23/12/2020 10:04pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ragosa Mark
2. Date of Event Requiring Statement (MM/DD/YYYY)
12/17/2020 

3. Issuer Name and Ticker or Trading Symbol

Kiniksa Pharmaceuticals, Ltd. [KNSA]
(Last)        (First)        (Middle)

CLARENDON HOUSE, 2 CHURCH STREET
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Interim CFO /
(Street)

HAMILTON, D0 HM 11      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option  (1)5/22/2028 Class A Common Shares 18299 $18.00 D  
Share Option  (2)9/19/2028 Class A Common Shares 20000 $30.93 D  
Share Option  (3)3/3/2029 Class A Common Shares 12000 $17.92 D  
Share Option  (4)9/16/2029 Class A Common Shares 12000 $8.83 D  
Share Option  (5)3/12/2030 Class A Common Shares 20000 $15.52 D  
Share Option  (6)9/9/2030 Class A Common Shares 22000 $15.50 D  
Restricted Share Units  (7) (7)Class A Common Shares 4404  (8)D  

Explanation of Responses:
(1) The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is May 10, 2018.
(2) The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 20, 2018.
(3) The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019.
(4) The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019.
(5) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020.
(6) The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020.
(7) The Restricted Share Units (RSU) will vest in a single installment on December 31, 2020, subject to the Reporting Person's continuous employment or service to the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSU.
(8) Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.

Remarks:
Exhibit 24 - Power of Attorney.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Ragosa Mark
CLARENDON HOUSE
2 CHURCH STREET
HAMILTON, D0 HM 11


Interim CFO

Signatures
/s/ Mark Ragosa12/23/2020
**Signature of Reporting PersonDate

1 Year Kiniksa Pharmaceuticals Chart

1 Year Kiniksa Pharmaceuticals Chart

1 Month Kiniksa Pharmaceuticals Chart

1 Month Kiniksa Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock